CN1158568A - 2，3-二氢-1(2，2，2-三氟乙基)-2-氧代-5-苯基-1h-1，4-苯并二氮杂䓬 - Google Patents
2，3-二氢-1(2，2，2-三氟乙基)-2-氧代-5-苯基-1h-1，4-苯并二氮杂䓬 Download PDFInfo
- Publication number
- CN1158568A CN1158568A CN95195291A CN95195291A CN1158568A CN 1158568 A CN1158568 A CN 1158568A CN 95195291 A CN95195291 A CN 95195291A CN 95195291 A CN95195291 A CN 95195291A CN 1158568 A CN1158568 A CN 1158568A
- Authority
- CN
- China
- Prior art keywords
- trifluoroethyl
- dihydro
- oxo
- phenyl
- benzo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940049706 benzodiazepine Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 47
- 239000003416 antiarrhythmic agent Substances 0.000 claims abstract description 22
- -1 chloro, fluoro, bromo, iodo Chemical group 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 239000001257 hydrogen Substances 0.000 claims abstract description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 10
- 239000013078 crystal Chemical group 0.000 claims abstract description 8
- 150000003839 salts Chemical group 0.000 claims abstract description 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 102
- 230000003288 anthiarrhythmic effect Effects 0.000 claims description 21
- 239000000460 chlorine Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 206010003119 arrhythmia Diseases 0.000 claims description 10
- 230000006793 arrhythmia Effects 0.000 claims description 10
- 229940117389 dichlorobenzene Drugs 0.000 claims description 10
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 claims description 9
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 239000011630 iodine Substances 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- 239000002327 cardiovascular agent Substances 0.000 claims description 5
- 229940125692 cardiovascular agent Drugs 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract description 2
- 150000004677 hydrates Chemical group 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 32
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- 238000004364 calculation method Methods 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 239000000376 reactant Substances 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 238000009834 vaporization Methods 0.000 description 12
- 230000008016 vaporization Effects 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 235000019439 ethyl acetate Nutrition 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000013019 agitation Methods 0.000 description 8
- 239000006260 foam Substances 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 150000002431 hydrogen Chemical class 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000003810 ethyl acetate extraction Methods 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 229960001866 silicon dioxide Drugs 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000003663 ventricular fibrillation Diseases 0.000 description 4
- HQRSIMQXCAWAJB-UHFFFAOYSA-N 3,3,3-trifluoro-2-phenylpropanoic acid Chemical class OC(=O)C(C(F)(F)F)C1=CC=CC=C1 HQRSIMQXCAWAJB-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000036982 action potential Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 206010042434 Sudden death Diseases 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 229960005260 amiodarone Drugs 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 150000008359 benzonitriles Chemical class 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 229960002370 sotalol Drugs 0.000 description 2
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- IRICHAOGAOFEQI-UHFFFAOYSA-N (1-bromo-2,2,2-trifluoroethyl)benzene Chemical compound FC(F)(F)C(Br)C1=CC=CC=C1 IRICHAOGAOFEQI-UHFFFAOYSA-N 0.000 description 1
- MAOBFOXLCJIFLV-UHFFFAOYSA-N (2-aminophenyl)-phenylmethanone Chemical compound NC1=CC=CC=C1C(=O)C1=CC=CC=C1 MAOBFOXLCJIFLV-UHFFFAOYSA-N 0.000 description 1
- BUJAGSGYPOAWEI-SECBINFHSA-N (2r)-2-amino-n-(2,6-dimethylphenyl)propanamide Chemical compound C[C@@H](N)C(=O)NC1=C(C)C=CC=C1C BUJAGSGYPOAWEI-SECBINFHSA-N 0.000 description 1
- ISEBNIQQPMISGA-OAHLLOKOSA-N (2r)-3-phenyl-2-(phenylmethoxyamino)propanoic acid Chemical compound C([C@H](C(=O)O)NOCC=1C=CC=CC=1)C1=CC=CC=C1 ISEBNIQQPMISGA-OAHLLOKOSA-N 0.000 description 1
- RKOUFQLNMRAACI-UHFFFAOYSA-N 1,1,1-trifluoro-2-iodoethane Chemical compound FC(F)(F)CI RKOUFQLNMRAACI-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- VYIBCOSBNVFEIW-UHFFFAOYSA-N 3-phenylpropanamide Chemical compound NC(=O)CCC1=CC=CC=C1 VYIBCOSBNVFEIW-UHFFFAOYSA-N 0.000 description 1
- YNHGHPCGMBEGEU-UHFFFAOYSA-N 5-phenyl-1h-1,4-benzodiazepine Chemical compound C12=CC=CC=C2NC=CN=C1C1=CC=CC=C1 YNHGHPCGMBEGEU-UHFFFAOYSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 241000208011 Digitalis Species 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 206010049447 Tachyarrhythmia Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- 229960002122 acebutolol Drugs 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960004895 bretylium tosylate Drugs 0.000 description 1
- KVWNWTZZBKCOPM-UHFFFAOYSA-M bretylium tosylate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.CC[N+](C)(C)CC1=CC=CC=C1Br KVWNWTZZBKCOPM-UHFFFAOYSA-M 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 229960001066 disopyramide Drugs 0.000 description 1
- 230000037024 effective refractory period Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000449 flecainide Drugs 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000936 membranestabilizing effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229940088938 norpace Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940117953 phenylisothiocyanate Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- 235000013926 potassium gluconate Nutrition 0.000 description 1
- 229960003189 potassium gluconate Drugs 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 1
- 229960000203 propafenone Drugs 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000036279 refractory period Effects 0.000 description 1
- 230000002336 repolarization Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960002872 tocainide Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
本发明涉及结构式(I)表示的作为抗心律失常药的新化合物和其所有各种异构形式的消旋物、对映体混合物、个别非对映体或个别对映体，以及它们的可药用盐、水合物或结晶形式其中X和Y各自独立地代表氢、氯、氟、溴、碘或三氟甲基，n是0、1或2，R是氢、氟、氯、溴、碘或三氟甲基、甲基或甲氧基。
Description
发明背景
心律失常经常作为诸如心肌梗塞形成和心力衰竭等心脏疾病的并发症发生。在严重的情形，心律失常会造成心室纤维性颤动并且能引起突然死亡。
虽然现在市场上已有各种抗心律失常药供应，但是还没有得到既有令人满意的效果、又是高度安全的药物。例如，根据Vaughan-Williams分类的第I类抗心律失常药会造成动作电位上向冲程最大速度(Vmax)的选择性抑制，不适合防止心室纤颤。另外，它们在安全性方面有问题，即，会引起心肌收缩力下降并且由于抑制了搏动传导而有诱发心律失常的倾向。β-肾上腺素能受体阻断剂和钙拮抗剂分属第II和第IV类，它们的缺点是其作用或是局限于一定类型的心律失常，或是因为它们的心抑制剂性能而不能用于患心血管疾病的某些病人。但是它们的安全性比第I类抗心律失常药要高。
第III类抗心律失常药是使动作电位的持续时间选择性延长而又不显著减少Vmax的药物。属于这一类的药物有限。诸如索他洛尔和胺碘酮等实例已显示出具有第III类性质。索他洛尔还具有第II类的作用，它可能引起心的抑郁，因此不能用于某些敏感的患者。另外，胺碘酮由于副作用而受到严重限制。这类药物预期在防止心室纤维性颤动方面有效。根据定义，纯的第III类药物不会象第I类抗心律失常药那样由于抑制动作电位传导而引起心肌收缩力下降或诱发心律失常。
发明概要
本发明涉及作为抗心律失常药的结构式(I)表示的新化合物及其所有各种异构形式的消旋物、对映体混合物、个别非对映体或个别对映体，以及它们的可药用的盐、水合物或结晶形式其中X和Y各自独立地是氢、氯、氟、溴、碘或三氟甲基，n是0、1或2；R是氢、氟、氯、溴、碘或三氟甲基、甲基或甲氧基。本发明还涉及含有一种这类新化合物作为活性组分的药物制剂。
本发明的化合物可以有不对称中心并以包括在本发明中的所有各种异构体形式的消旋物、对映体混合物、个别非对映体或个别对映体的形式存在。
本发明还涉及一种治疗心律失常的方法，其作法是使需要这种治疗的患者服用一种上述的新化合物或其制剂。发明详述
本发明的新化合物是作为抗心律失常药的用结构式I表示的化合物和所有各种异构体形式的消旋物、对映体混合物、个别非对映体或个别对映体，以及它们的可药用盐、水合物或结晶形式
其中X和Y各自独立地代表氢、氯、氟、溴、碘，或是三氟甲基，n是0、1或2，R是氢、氟、氯、溴、碘或三氟甲基、甲基或甲氧基。本发明的化合物可以有不对称中心并以包括在本发明中的所有各种异构体形式的消旋物、对映体混合物、个别非对映体或个别对映体的形式存在。
本发明还涉及一种治疗心律失常的方法，其作法是使需要治疗的患者服用一种这类新化合物或其制剂。
本发明的最优选的实施方案是(-)-2-〔2，4-双(三氟甲基)苯基〕-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺
本发明新化合物的另一实施方案是(+)-3，5-二氯-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕苯甲酰胺
本发明新化合物的又一实施方案是(-)-2-(3，4-二氯苯基)-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺
本发明新化合物的另一实施方案是(-)-2-(3，5-二氯苯基)-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺
本发明实施方案的其它实例是：3-环己基-N-〔5-(2-氟苯基)-2-氧代-1-(2，2，2-三氟乙基)-2，3-二氢-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕丙酰胺3，4-二氯-N-〔5-(2-氟苯基)-2-氧代-1-(2，2，2-三氟乙基)-2，3-二氢-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕苯甲酰胺
(-)-2-〔3，5-双(三氟甲基)苯基〕-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺(-)-2-(4-三氟甲基苯基)-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺(-)-2-(3-三氟甲基苯基)-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺(-)-2-(2-三氟甲基苯基)-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺(-)-2-(2，4-二氯苯基)-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺(-)-2-(3-氯苯基)-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺
(-)-2-(4-氯苯基)-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4 〕二氮杂-3-基〕乙酰胺(+)-2-(3，5-二氯苯基)-N-〔2，3-二氢-2-氧代-5-(4-氟苯基)-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺(-)-2-(2，4-二氯苯基)-N-〔2-氧代-5-(4-氟苯基)-1-(2，2，2-三氟乙基)-2，3-二氢-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺
(+)-2-〔3，5-双(三氟甲基)苯基〕-N-〔2-氧代-5-(4-氟苯基)-1-(2，2，2-三氟乙基)-2，3-二氢-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺
(-)-2-〔2，4-双(三氟甲基)苯基〕-N-〔2-氧代-5-(4-氟苯基)-1-(2，2，2-三氟乙基)-2，3-二氢-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺2-(3，5-二氯苯基)-N-〔2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺
在下面的方案I中示意举例说明了一种制备本发明化合物的新方法，这些步骤在工艺上是众所周知的，并且/或者在随后的实施例中说明。
方案1
方案1续
本发明的新化合物具有第III类抗心律失常药所要求的药理性质，即，它们显示出QTc间期延长和与剂量有关的心室不应期增大。同时对心率、平均动脉血压以及PR和QPS间期无影响。观察到LV+dp/dt(左心室的压力随时间变化)有适度的变化。另外，这些化合物抑制由PVS(程序化心室刺激)诱发的快速性心律失常的发生。
这些化合物在治疗和预防所有各类心律失常方面有效，包括心室和动脉(室上)心律失常。本发明化合物特别适用于控制再发性心律失常和防止由于心室纤维性颤动导致的猝死。这些化合物在治疗和预防受损的心泵功能方面也有效。
在本发明治疗心律失常的新方法中，上述一种化合物或其可药用盐的服用量是每kg体重每天约0.0001至约10mg，优选每kg体重每天约0.0001至约2mg，最好是每kg体重每天经静脉内注入约0.0003至约0.3mg，或者在口服时每Kg体重每天约0.03至约1mg，一次服用或分成2-4次服用。
这些化合物或其可药用的盐按所述的剂量以口服、腹膜内、皮下、肌内、经皮、舌下或静脉内等方式用药。它们最好是静脉内或口服用药，例如以片剂、锭剂、胶囊、酏剂、悬浮液、乳剂、糖浆、糯米纸囊剂、咀嚼胶剂或者经工艺上认可的步骤制备的其它类似形式。在这类适用于治疗的组合物或制剂中，活性化合物应该有能得到合适剂量的数量。
这些化合物可以作为唯一的活性组分服用，或是与其它的抗心律失常药或其它的心血管药物结合服用，例如第I、II或IV类抗心律失常药、血管舒张药、血管紧张肽转化酶抑制剂、血管紧张肽II拮抗剂、利尿药或洋地黄。
可以与使用去纤维性颤动器(包括可植入的去纤维性颤动器)相配合服用这些化合物作为治疗心律失常和受损的心泵功能的一种方法。这些化合物减小去纤维性颤动器起动的频率。
第一类抗心律失常药是指这些药物对钠通道提供阻断作用，这包括具有膜稳定作用的那些化合物。这类化合物的实例是奎尼丁、普鲁卡因酰胺、双异丙吡胺、利多卡因、妥卡尼、氟卡尼和普罗帕酮。第二类抗心律失常化合物是阻断交感神经活性的药物。这类化合物的实例是普萘洛尔和醋丁洛尔。第III类抗心律失常药是延长有效不应期而又不改变静息膜电位或去极化速度的化合物。除了本发明的新化合物之外，诸如乙胺碘酮、溴苄铵和索他洛尔等化合物也被认为属于此类。第IV类抗心律失常药在阻断钙通道方面有效。这类化合物的实例是地尔硫卓和维拉帕米。在药物规划(Pharma Project)C1B，1993年5月号中可以找到对这些类别的进一步定义，该文献在这里引用作为参考。
血管舒张药的实例是例如罂粟碱和硝酸异山梨酯等化合物。血管紧张肽转化酶抑制剂的实例包括依那普利、赖诺普利和卡托普利。利尿剂的实例包括氢氯噻嗪和乙酰唑胺。这里列出的药剂只是实例，不代表本发明所考虑的许多这类化合物的完整名单。
这里提到的各种化合物作为抗心律失常药的活性按照以下实验方案通过测定它们阻断IKs和IKr电流的能力来确定。
外向钾电流是用在另文中详述〔Sanguinetti和Jurkiewicz，1990，心脏延迟整流器K+电流的两个组分：对于第III类抗心律失常药阻断作用的微分灵敏度。普通生理杂志(J.Gen.Physiol)，96：195-215〕的全细胞电压箱技术在单个豚鼠心室肌细胞中测定。肌细胞是用酶(胶原酶和蛋白酶)切消化法由兰根道尔夫法灌注的心脏分离。然后用充满0.5M葡萄糖酸钾、25mM KCl、5mM腺苷三磷酸二钾盐的1mm方孔移液吸管对单个细胞进行电压箱制。细胞浸泡在以下成分的溶液中：132mN NaCl，4mN KCl，1.2mN MgCl2，10mN HEPES，10mN葡萄糖，pH为7.2，温度35℃。
各细胞保持吸持电位-50mV。当电压由-85mV滑升到-50mV以及跃升到-10mV(0.5秒)和+50mV(1.0秒)时施加试验去极化作用。IKI是作为电压滑升期间的峰值外向电流测量。IKr是作为从-10mV到-50mV复极化时的尾电流测量。在调控期间测定电流，然后在暴露于两种不同浓度的药物之后再测定电流。
采用这种试验方法，本文所述的化合物作为IKs阻断剂的IC50小于100nM。本发明的化合物阻断IKs的能力比阻断IKr至少强10倍。
实施例
实施例1(+)-3，5-二氯-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂草-3-基〕苯甲酰胺
步骤A：2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)
-1H-苯并〔e〕〔1，4〕二氮杂的制备
将5-苯基-1，4-苯并二氮杂-2-酮〔J.Org.Chen.(有机化学杂志)，1962，27，3788〕(50g，0.211mole)在二甲基甲酰胺(100ml)中的溶液用碳酸铯(103.5g，0.317mole)和三氟乙基碘(109.7g，0.525mole)处理。将混合物在50℃搅拌过夜。然后将反应混合物倒入2L水中，用乙酸乙酯萃取(3×1L)。合并的乙酸乙酯级分用无水硫酸镁干燥，过滤，减压浓缩。残余物自乙醚中重结晶，得到45g(68％)产物。熔点130-131℃；1H NMR(CDCl3，300MHz)δ7.65-7.60(m，2H)，7.60-7.45(m，5H)，7.40-7.20(m，2H)，5.25(dp，J＝14，8.6Hz，1H)，4.82(d，J＝10.5Hz，1H)，4.15(近似六重峰，J＝8.6Hz，1H)，3.81(d，J＝10.5Hz，1H)步骤B：3-叠氮基-5-苯基-1-(2，2，2-三氟乙基)-1H-苯
并[e][1，4]二氮杂的制备
在搅拌下于15分钟内向冷却到-70℃的5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂(70g，0.22mol)在四氢呋喃(1500ml)中的溶液里逐滴加入叔丁醇钾(1.1当量，0.24mol，240ml在1N四氢呋喃中的溶液)。5分钟内加入2，4，6-三异丙基苯磺酰叠氮(74.8g，0.24mol)在四氢呋喃(250ml)中的溶液。搅拌10分钟，加入乙酸(40ml，0.63mol)，使反应物温热至环境温度。将反应物倒入饱和的NaHCO3(1500ml)和乙酸乙酯(11)中。分离出各相，水相用乙酸乙酯(500ml)萃取。合并的有机层依次用水(500ml)和盐水(300ml)洗。有机层用Na2SO4干燥，蒸发成褐色泡沫状物。将它用乙醚研制，得到65g白色粉末。将滤液浓缩，在硅胶上层析，用30％的乙酸乙酯/己烷洗脱，得到另外的8.9g。合并的产量为74g(93％)。熔点＝159-160℃；1H NMR(CDCl3，300MHz)δ7.70-7.26(m，9H)，5.28-5.12(m，1H)，4.63(s，1H)，4.35-4.10(m，1H)。步骤C：消旋的3-氨基-5-苯基-1-(2，2，2-三氟乙基)-1H
-苯并〔e〕〔1，4〕二氮杂的制备
在搅拌下向3-叠氮基-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-2，3-二氢-1H-苯并[e][1，4]二氮杂(83.4mmol，30g)在300ml乙醇和150ml四氢呋喃中的溶液里加入10％Pd/C(10％重量，3.0g)。向溶液中鼓入氢气8小时。将反应物过滤，减压蒸发。残余物自乙醚中结晶，得到20.0g白色晶体。从滤液蒸发和重结晶中得到另外的4g。总产率为86.7％。熔点＝141-143℃；1H NMR(CDCl3，300MHz)δ7.70-7.26(m，9H)，5.28-5.12(m，1H)，4.57(s，1H)，4.35-4.10(m，1H)。步骤D：2-氨基-N-〔2-氧代-5-苯基-1-(2，2，2-三氟乙基)-2，3-二氢-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕-3-苯基丙酰胺的制备
在搅拌下向3-氨基-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-2，3-二氢-1H-苯并〔e〕〔1，4〕二氮杂(92.2mmol，30.74g)在二甲基甲酰胺(300ml)中的溶液里加入N-苄氧基-D-苯基丙氨酸(92.2mmol，27.6g)、1-(3-二甲氨基丙基)-3-乙基碳化二亚胺盐酸盐(0.12mol，22.95g)和1-羟基苯并三唑水合物(46.1mmol，6.23g)。在室温下搅拌2小时。然后用1L 10％KHSO4稀释，用乙酸乙酯(2×600ml)萃取。将有机层合并，用饱和的碳酸氢钠溶液(600ml)洗。将其用盐水和硫酸钠干燥，减压蒸发。得到66.58g橙色泡沫状物，根据NMR其中含有乙酸乙酯。NMR1H(CDCl3)δ7.75-7.18(m，20H)，5.62-5.55(m，1H)，5.48-5.00(m，4H)，4.72-4.60(m，1H)，4.25-4.05(m，1H)，3.32-3.05(m，2H)。此物质不经进一步纯化直接用于下一步骤。
在搅拌下向2-(N-苄氧基氨基)-N-〔2-氧代-5-苯基-1-(2，2，2-三氟乙基)-2，3-二氢-1H-苯并〔e〕〔1，4〕二氮杂草-3-基〕-3-苯基丙酰胺1L乙醇中的溶液里加入10％Pd/C(15％重量)，向反应物中鼓入氢气2小时，然后在1个大气压的氢气下搅拌过夜。次日上午再向反应物中鼓入氢气3小时。然后将反应物过滤，催化剂用1L二氯甲烷洗，减压蒸发。所得的固体真空干燥过夜，得到44.46g白色固体。将其在硅胶上层析，用1％MeOH∶EtOAc洗脱。收集较高Rf的纯级分并减压蒸发。收集混合级分，蒸发并再层析。收集纯的级分，与上述的纯级分合并，得到较高Rf非对映体的总产量为18.11g，产率83.5％。1H NMR(CDCl3，300MHz)δ8.94(d，J＝8.6Hz，1H)，7.65-7.10(m，9H)，5.64(d，J＝8.6Hz，1H)，5.28-5.12(m，1H)，4.57(s，1H)，4.35-4.10(m，1H)，3.71(dd，J＝9.8和3.9Hz，1H)，3.34(dd，J＝13.9和3.9Hz，1H)，2.79(dd，J＝13.9和10.0Hz，1H)。用X-射线分析确定，在苯并二氮杂的C-3上绝对立体化学构型为(R)。
相应于C-3(S)的低Rf的物质也同样分离。步骤E：3(R)-(+)-3-氨基-5-苯基-1-(2，2，2-三
氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂的制备
在搅拌下向2-氨基-N-〔2-氧代-5-苯基-1-(2，2，2-三氟乙基)-2，3-二氢-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕-3-苯基丙酰胺(13.6g，28.3mmol)在二氯甲烷(136ml)中的溶液里加入异硫氰酸苯酯(3.87ml，34.0mmol)。在环境温度下搅拌过夜。然后将反应物在冰中冷却；加入三氟乙酸(2.73ml，0.283mol)，令反应物温热至环境温度。在环境温度下搅拌2.5小时后，将反应物减压蒸发，用90∶10∶1∶1的二氯甲烷∶甲醇∶乙酸∶水进行层析。收集低Rf点，不加热减压蒸发。将残余物溶在600ml二氯甲烷中，用300ml饱和NaHCO3溶液和300ml水洗。溶液用Na2SO4干燥，减压蒸发。残余物自乙酸乙酯∶己烷中结晶，得到6.65g白色粉末。熔点162-164℃；1H NMR(CDCl3，300MHz)δ7.70-7.26(m，9H)，5.28-5.12(m，1H)，4.57(s，1H)，4.35-4.10(m，1H)。[α]D＝+72.9°(c＝0.7，MeOH)
按同样方式由步骤D的较低Rf的产物制备(-)-3S对映体。熔点156-158℃；1H NMR(CDCl3，300MHz)δ7.70-7.26(m，9H)，5.28-5.12(m，1H)，4.57(s，1H)，4.35-4.10(m，1H)。[α]D＝-71.2°(c＝0.66，MeOH)步骤F：(+)-3，5-二氯-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂草-3-基〕苯甲酰胺的制备
在搅拌下向(+)-3R-3-氨基-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂(5.6g，16.8mmol)在二甲基甲酰胺(50ml)中的溶液里加入1-(3-二甲氨基丙基-3-乙基碳化二亚胺盐酸盐(4.44g，23.0mmol)、1-羟基苯并三唑水合物(3.11g，23.0mmol)和3，5-二氯苯甲酸(3.21g，16.8mmol)。在环境温度下搅拌2小时。将反应物用500ml饱和NaHCO3溶液稀释，用2×300ml乙酸乙酯萃取。合并的有机物用10％KHSO4(200ml)、盐水(200ml)洗，在Na2SO4上干燥，蒸发成白色泡沫状物。将其在75×200mm的硅胶柱上层析，用20％的乙酸乙酯∶己烷洗脱。收集纯级分，减压蒸发，得到8.5g白色泡沫状物，将其自15％的乙酸乙酯∶己烷中结晶，得到5.3g白色粉末。熔点140-143℃[α]D＝+47.9°1H NMR(CDCl3，300MHz)δ7.85-7.75(m，2H)，7.70-7.20(m，9H)，5.78(d，J＝8.1Hz、1H)，5.30-5.15(m，1H)，4.30-4.15(m，1H)。C24H16Cl2F3N3O2分析计算值：C，56.93；H，3.19；N，8.30；实验值：C，56.81；H，3.17；N，8.17。
利用与实施例1步骤F基本上相同的步骤制备以下实施例化合物。
实施例2(-)-2-(3，4-二氯苯基)-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺
mp＝219-221℃；[α]D＝-10.8°；1H NMR(CDCl3，300MHz)δ7.65-7.15(m，12H)，5.78(d，J＝8.1Hz，1H)，5.25-5.10(m，1H)，4.254.05(m，1H)，3.56(s，2H)；C25H18Cl2F3N3O2·0.85H2O分析计算值：C，56.06；H，3.71；N，7.84；实验值：C，56.03；H，3.53；N，7.82。
实施例3(-)-2-(3，5-二氯苯基)-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺mp＝93-100℃，[α]D＝-5.7°；1H NMR(CDCl3，300MHz)δ7.65-7.15(m，12H)，5.78(d，J＝8.1Hz，1H)，5.25-5.10(m，1H)，4.25-4.05(m，1H)，3.65(s，2H)；C25H18Cl2F3N3O2分析计算值：C，57.71；H，3.49；N，8.08；实验值：C，57.41；H，3.48；N，8.12。
实施例4(-)-2-〔3，5-双(三氟甲基)苯基〕-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺
m.p.成泡沫体，[α]D＝-9.7°(c＝0.59，MeOH)C27H18F9N3O2·0.75H2O分析计算值：C，53.96；H，3.27；N，6.99；实验值：C，53.96；H，3.1；N，6.98％
实施例5(-)-2-(4-三氟甲基苯基)-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺m.p.253-255℃[α]D＝-9.2°(c＝0.25，MeOH)C26H19F6N3O2·0.05乙醚0.55H2O分析计算值：C，59.03；H，3.9；N，7.88.实验值：C，59.05；H，3.82；N，7.78％.
实施例62-(3-三氟甲基苯基)-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺熔点172-173℃[α]D＝+5.9°(c＝0.56，CHCl3)C26H19F6N3O2·0.60H2O分析计算值：C，58.89；H，3.84；N，7.92实验值：C，58.92；H，3.71；N，7.98％
实施例7(+)-2-(2-三氟甲基苯基)-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺m.p.170-171℃[α]D＝+9.0°(c＝0.48，CHCl3)C26H19F6N3O2·0.25H2O分析计算值：C，59.6；H，3.75；N，8.02；实验值：C，59.64；H，3.68；N，7.97％
实施例8(-)-2-(2，4-二氯苯基)-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺m.p.143-145℃[α]D＝-22.6°(c＝0.73，MeOH)C25H18N3O2Cl2F3分析计算值：C，57.71；H，3.49；N，8.08；实验值：C，57.75；H，3.52；N，8.09％
实施例9(-)-2-(3-氯苯基)-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺
m.p.188-189℃[α]D＝-5.4°(c＝1.03，MeOH)C25H19ClF3N3O2·0.10乙醚分析计算值：C，61.84；H，4.09；N，8.52；实验值：C，61.84；H，4.05；N，8.5％
实施例10(-)-2-(4-氯苯基)-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1 H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺m.p.246-247℃，[α]D＝-10.1 °(c＝0.45，MeOH).C25H19ClF3N3O2·0.20H2O 0.15乙醚分析计算值：C，61.42；H，4.21；N，8.39；实验值：C，61.46；H，4.15；N，8.39％
实施例11(-)-2-〔2，4-双(三氟甲基)苯基〕-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺
步骤A：2，4-双(三氟甲基)苄腈
在搅拌下于30分钟内向加热到60℃的100ml乙醇和250ml磷酸盐缓冲液(每5ml水1g NaH2PO4·H2O，用50％NaOH调节到pH＝7.0)及NaCN(81.3mmol，4.0g)的两相混合物中逐滴加入2，4-双(三氟甲基)苄基溴(32.5mmol，10g)在50ml乙醇中的溶液。将反应混合物在60℃加热24小时。然后减压蒸发。剩余的水相用2×150ml乙酸乙酯萃取。将有机层合并，用盐水和Ba2SO4干燥。将有机相减压蒸发，残余物在硅胶上层析，用10％乙酸乙酯∶己烷洗脱。收集纯级分，蒸发，得到7.0g浅黄色油状物，产率85.1％，NMR1H(CDCl3)δ 8.0-7.85(m，3H)，4.03(s，2H)。步骤B：2，4-双(三氟甲基)苯乙酸
将2，4-双(三氟甲基)苄腈(41.5mmol，10.51g)溶在100ml乙酸、50ml浓硫酸和20ml水中。加热至120℃保持3小时。然后用1L冰水冲稀反应物，用2×300ml乙酸乙酯萃取。将合并的有机物用2×200ml水洗，用盐水和Na2SO4干燥，减压蒸发。残余物溶在最少量的乙醚中，加入足量的己烷使产物结晶沉淀。收集固体，得到7.74g白色晶体状的2，4-双(三氟甲基)苯乙酸，产率68.5％NMR1H(CDCl3)δ7.93(s，1H)，7.80(d，J＝7.9Hz，1H)，7.55(d，J＝7.9Hz，1H)3.94(s，2H)。步骤C：(-)-2-〔2，4-双(三氟甲基)苯基〕-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺
在搅拌下向3R-3-氨基-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-2，3-二氢-1H-苯并〔e〕〔1，4〕二氮杂(28.4mmol，9.47g)在二甲基甲酰胺(100ml)中的溶液里加入2，4-双(三氟甲基)苯乙酸(28.4mmol，7.74g)，1-(3-二甲氨基丙基)-3-乙基碳化二亚胺盐酸盐(42.6mmol，8.16g)和1-羟基苯并三唑水合物(14.2mmol，1.92g)。在室温下搅拌1小时。然后用750ml的10％KHSO4将反应物稀释，用乙酸乙酯萃取(2×300ml)。将有机层合并，用饱和的碳酸氢钠溶液洗(1×600ml)。然后用盐水和硫酸钠将有机物干燥，减压蒸发。残余物在硅胶上层析，用20％的乙酸乙酯∶己烷洗脱。收集纯级分并蒸发之。残余物溶在100ml温热的75％异丙醇∶水中。令其缓慢冷却，在室温下搅拌过夜(16小时)。将此悬浮液短暂地冷却到5℃并过滤。将白色固体在60℃干燥过夜，得到10.5g物质，其熔点为132-134℃。X射线衍射证实其结晶性。NMR1H(CDCl3)δ7.95-7.25(m，13H)，5.60(d，J＝8.1Hz，1H)，5.30-5.10(m，1H)，4.25-4.06(m，1H)，3.96(s，2H)C27H18F9N3O2分析计算值：C，55.20；H，3.09；N，7.15；实验值：C，55.03；H，3.14；N，7.10％
实施例12(±)-2-(3，5-二氯苯基)-N-〔2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺
m.p.219-220℃.外消旋C25H18N3O2Cl2F3分析计算值：C，57.71；H，3.49；N，8.08；实验值：C，57.94；H，3.48；N，8.02％
实施例132-(3，5-二氯-4-甲氧基苯基)-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺
m.p.100-104℃，[α]D＝-8.9°(c＝0.55，MeOH).C26H20Cl2F3N3O3分析计算值：C，56.74；H，3.66；N，7.63；实验值：C，55.67；H，3.47；N，7.41％
以下实施例是用与实施例1中所述基本上相同的步骤制备，但是在步骤A中用合适的氟代氨基苯酮代替。
实施例14(+)-2-(3，5-二氯苯基)-N-〔2，3-二氢-5-(4-氟苯基)-2-氧代-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺m.p.成泡沫体，[α]D＝+3.4°(c＝0.55，MeOH)C25H17N3O2Cl2F4分析计算值：C，55.78；H，3.18；N，7.81；实验值：C，55.73；H，3.25；N，7.72％
实施例15(-)-2-(2，4-二氯苯基)-N-〔2，3-二氢-5-(4-氟苯基)-2-氧代-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺m.p.成泡沫体，[α]D＝-1.1°(c＝0.68，MeOH)C25H17N3O2F4分析计算值：C，55.78；H，3.18；N，7.81；实验值：C，55.82；H，3.41；N，7.42％
实施例16(+)-2-〔3，5-双(三氟甲基)苯基〕-N-〔2，3-二氢-5-(4-氟苯基)-2-氧代-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺m.p.成泡沫体，[α]D＝+2.8°(c＝0.67，MeOH)C27H17N3O2F10分析计算值：C，53.56；H，2.83；N，6.94；实验值：C，53.56；H，2.93；N，6.91％
实施例17(-)-2-〔2，4-双(三氟甲基)苯基〕-N-〔2，3-二氢-5-(4-氟苯基)-2-氧代-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺[α]D＝-14°(c＝0.63；MeOH).C27H17N3O2F10分析计算值：C，53.56；H，2.83；N，6.94；实验值：C，53.3；H，2.89；N，7.05％
实施例183-环己基-N-〔2，3-二氢-5-(2-氟苯基)-2-氧代-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕丙酰胺m.p.202-204℃1H NMRδ(CDCl3，)7.72(m，8H)，5.65(d，J＝8.3Hz，1H)，5.35-5.08(m，1H)，4.32-4.15(m，1H)2.37(t，J＝7.8Hz，2H)，1.80-1.55(m，7H)，1.45-C26H27F4N3O2分析计算值：C，63.8；H，5.56；N，8.58；实验值：C，63.82；H，5.54；N，8.56％
实施例193，4-二氯-N-〔2，3-二氢-5-(2-氟苯基)-2-氧代-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕苯甲酰胺
m.p.168-170℃.1H NMRδ(CDCl3)8.03(d，J＝2.0，1H)，7.86(d，J＝7.8Hz，1H)，7.78-7.05(m，9H)，5.80(d，J＝7.8Hz，1H)，5.27-5.15(m，1H)，4.35-4.20(m，1H)C24H15Cl2F4N3O2分析计算值：C，54.98；H，2.88；N，8.01，实验值：C，54.96；H，2.89；N，8.12％
Claims (14)
1.作为抗心律失常药的结构式I化合物和其所有各种异构形式的消旋物、对映体混合物、个别非对映体或个别对映体，以及它们的可药用盐、水合物或结晶形式其中X和Y各自独立地是氢、氯、氟、溴、碘或三氟甲基，n是0、1或2，R是氢、氟、氯、溴、碘或三氟甲基、甲基或甲氧基。
2.权利要求1的化合物，选自：(-)-2-〔2，4-双(三氟甲基)苯基〕-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺(+)-3，5-二氯-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕苯甲酰胺(-)-3，4-二氯苯基-1-基-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺
(-)-2-(3，5-二氯苯基)-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺3-环己基-N-〔2，3-二氢-5-(2-氟苯基)-2-氧代-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕丙酰胺
3，4-二氯-N-〔2，3-二氢-5-(2-氟苯基)-2-氧代-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕苯甲酰胺
(-)-2-〔3，5-双(三氟甲基)苯基〕-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺(-)-2-(4-三氟甲基苯基)-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺(-)-2-(3-三氟甲基苯基)-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺(-)-2-(2-三氟甲基苯基)-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺
(-)-2-(2，4-二氯苯基)-N-〔3R-2，3-二氢-1-(2，2，2-三氟乙基)-2-氧代-5-苯基-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺(-)-2-(3-氯苯基)-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺(-)-2-(4-氯苯基)-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺(+)-2-(3，5-二氯苯基)-N-〔2，3-二氢-5-(4-氟苯基)-2-氧代-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺(-)-2-(2，4-二氯苯基)-N-〔2，3-二氢-5-(4-氟苯基)-2-氧代-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺
(+)-2-〔3，5-双(三氟甲基)苯基〕-N-〔2，3-二氢-5-(4-氟苯基)-2-氧代-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺(-)-2-〔2，4-双(三氟甲基)苯基〕-N-〔2，3-二氢-5-(4-氟苯基)-2-氧代-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺(±)-2-(3，5-二氯苯基)-N-〔2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺
2-(3，5-二氯-4-甲氧基苯基)-N-〔2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺
3.权利要求1的化合物(+)-3，5-二氯-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕苯甲酰胺
4.权利要求1的化合物(-)-2-(3，4-二氯苯基)-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺
5.权利要求1的化合物(-)-2-(3，5-二氯苯基)-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺
6.权利要求1的化合物(-)-2-〔2，4-双(三氟甲基)苯基〕-N-〔3R-2，3-二氢-2-氧代-5-苯基-1-(2，2，2-三氟乙基)-1H-苯并〔e〕〔1，4〕二氮杂-3-基〕乙酰胺
7.一种药物制剂，其中含有一种可药用的载体和治疗上有效数量的一种权利要求1的化合物或其可药用的盐、结晶形式或水合物。
8.权利要求7的药物制剂，其中还含有另一种抗心律失常药或其它的心血管药物。
9.一种预防或治疗心律失常的方法，该方法包括使需要这种治疗的患者服用对于抗心律失常是有效数量的权利要求1化合物。
10.权利要求9的方法，其中包括同时服用另一种抗心律失常药或其它的心血管药物。
11.一种药物制剂，其中含有一种可药用的载体和治疗上有效数量的权利要求6化合物或其可药用的盐、结晶形式或水合物。
12.权利要求11的药物制剂，其中还含有另一种抗心律失常药或其它的心血管药物。
13.一种预防或治疗心律失常的方法，该方法包括使需要这种治疗的患者服用对于抗心律失常是有效数量的权利要求6的化合物。
14.权利要求13的方法，其中包括同时服用另一种抗心律失常药或其它的心血管药物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29244794A | 1994-08-18 | 1994-08-18 | |
| US08/292,447 | 1994-08-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1158568A true CN1158568A (zh) | 1997-09-03 |
Family
ID=23124712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN95195291A Pending CN1158568A (zh) | 1994-08-18 | 1995-08-17 | 2，3-二氢-1(2，2，2-三氟乙基)-2-氧代-5-苯基-1h-1，4-苯并二氮杂䓬 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US5658901A (zh) |
| EP (1) | EP0776208B1 (zh) |
| JP (1) | JPH10504570A (zh) |
| KR (1) | KR970705395A (zh) |
| CN (1) | CN1158568A (zh) |
| AT (1) | ATE186463T1 (zh) |
| AU (1) | AU692300B2 (zh) |
| BG (1) | BG63032B1 (zh) |
| BR (1) | BR9508608A (zh) |
| CA (1) | CA2195974C (zh) |
| CZ (1) | CZ285008B6 (zh) |
| DE (1) | DE69513295T2 (zh) |
| DK (1) | DK0776208T3 (zh) |
| ES (1) | ES2139933T3 (zh) |
| FI (1) | FI970668A0 (zh) |
| GR (1) | GR3032592T3 (zh) |
| HU (1) | HU220635B1 (zh) |
| MX (1) | MX9701195A (zh) |
| NO (1) | NO970731L (zh) |
| NZ (1) | NZ291988A (zh) |
| PL (1) | PL319104A1 (zh) |
| RU (1) | RU2149161C1 (zh) |
| SK (1) | SK282019B6 (zh) |
| WO (1) | WO1996005839A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1694874B (zh) * | 2002-09-20 | 2010-06-09 | 阿罗治疗有限公司 | 苯并二氮杂*衍生物以及包含它们的药用组合物 |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5631251A (en) * | 1995-06-07 | 1997-05-20 | Merck & Co., Inc. | 5-cyclopropyl-1,4 benzodiazepine-2-ones |
| US5776930A (en) * | 1996-06-28 | 1998-07-07 | Merck & Company, Inc. | Pharmaceutical preparation |
| EP0907644A4 (en) * | 1996-06-28 | 2003-02-05 | Merck & Co Inc | PHARMACEUTICAL PREPARATION |
| US6635632B1 (en) | 1996-12-23 | 2003-10-21 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| US6683075B1 (en) | 1996-12-23 | 2004-01-27 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use |
| WO1998037068A1 (en) | 1997-02-21 | 1998-08-27 | Bristol-Myers Squibb Company | Benzoic acid derivatives and related compounds as antiarrhythmic agents |
| US6048877A (en) * | 1997-02-21 | 2000-04-11 | Bristol-Myers Squibb Company | Tetralone derivatives as antiarrhythmic agents |
| US6262068B1 (en) | 1997-02-21 | 2001-07-17 | Bristol-Myers Squibb Company | Lactam derivatives as antiarrhythmic agents |
| US5817658A (en) * | 1997-03-14 | 1998-10-06 | Merck & Company, Inc. | Method for treating Meniere's disease |
| GB2328942A (en) * | 1997-09-05 | 1999-03-10 | Merck & Co Inc | Side chain synthesis for an antiarrythmic compound |
| US6214823B1 (en) | 1997-10-17 | 2001-04-10 | Merck & Co., Inc. | Benzodiazepine derivatives as antiarrhythmic agents |
| ES2148057B1 (es) * | 1998-01-05 | 2001-05-16 | Univ Murcia | Nuevo uso del diacepam como potenciador del efecto de los inhibidores pde 3 |
| US6664250B2 (en) | 1998-01-20 | 2003-12-16 | Bristol-Myers Squibb Co. | Lactam derivatives as antiarrhythmic agents |
| US6528505B1 (en) | 1998-06-22 | 2003-03-04 | Elan Pharmaceuticals, Inc. | Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| US6509331B1 (en) | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| US6569851B1 (en) | 1998-06-22 | 2003-05-27 | Elan Pharmaceutials, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| US6774125B2 (en) * | 1998-06-22 | 2004-08-10 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| US6958330B1 (en) | 1998-06-22 | 2005-10-25 | Elan Pharmaceuticals, Inc. | Polycyclic α-amino-ε-caprolactams and related compounds |
| US6552013B1 (en) | 1998-06-22 | 2003-04-22 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| JP4410328B2 (ja) * | 1998-12-14 | 2010-02-03 | 久光製薬株式会社 | オキソクアゼパムの製造方法 |
| US20050192265A1 (en) * | 2003-03-20 | 2005-09-01 | Thompson Richard C. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds |
| CU20090172A6 (es) | 2009-10-09 | 2011-10-05 | Facultad De Quimica Universidad De La Habana | Sistemas tricíclicos y tetracíclicos con actividad sobre el sistema nervioso central y vascular |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT75373B (en) * | 1981-08-12 | 1986-06-18 | Agripat Sa | Process for the preparation of tinted contact lenses |
| DE3134672A1 (de) * | 1981-09-02 | 1983-03-17 | Boehringer Ingelheim KG, 6507 Ingelheim | Heterocyclische verbindungen, ihre herstellung und verwendung |
| US4473575A (en) * | 1982-07-19 | 1984-09-25 | Ciba-Geigy Corporation | 3-Amino-(1)-benzazepin-2-one-1-alkanoic acids |
| DE3373469D1 (en) * | 1982-09-30 | 1987-10-15 | Merck & Co Inc | 1-n-alkylcarboxy-benzofused lactams useful as antihypertensive agents |
| DK151808C (da) * | 1982-11-16 | 1988-06-20 | Ferrosan As | Analogifremgangsmaade til fremstilling af oxadiazolylimidazo-oe1,4aa-benzodiazepinderivater |
| US4470988A (en) * | 1983-02-10 | 1984-09-11 | Ciba-Geigy Corporation | Benzazocinone and benzazoninone derivatives, and their pharmaceutical use |
| US4537885A (en) * | 1983-02-10 | 1985-08-27 | Ciba Geigy Corporation | Certain benzazocinone and benzazoninone derivatives |
| EP0150040B1 (de) * | 1984-01-19 | 1994-08-31 | F. Hoffmann-La Roche Ag | Imidazodiazepin-Derivate |
| US4600534A (en) * | 1984-02-06 | 1986-07-15 | Ciba-Geigy Corporation | Process and intermediates for manufacture of 3-(5-amino-1-carboxypentylamino)-tetrahydro-1-benzazepin-2-one-1-acetic acid |
| US4820834A (en) * | 1984-06-26 | 1989-04-11 | Merck & Co., Inc. | Benzodiazepine analogs |
| CA1332410C (en) * | 1984-06-26 | 1994-10-11 | Roger M. Freidinger | Benzodiazepine analogs |
| US5004741A (en) * | 1984-06-26 | 1991-04-02 | Merck & Co., Inc. | Methods of antagonizing CCK or gastrin with benzodiazepine analogs |
| US4692522A (en) * | 1985-04-01 | 1987-09-08 | Merck & Co., Inc. | Benzofused lactams useful as cholecystokinin antagonists |
| US4847248A (en) * | 1986-12-23 | 1989-07-11 | Merck & Co., Inc. | 1,4-Benzodiazepines with 5- and 6-membered heterocyclic rings and their use as cholecystokinins and gastrin antagonists |
| EP0348523A4 (en) * | 1987-12-22 | 1991-10-09 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienodiazepine compounds and their medicinal use |
| EP0322779A3 (en) * | 1987-12-29 | 1991-05-08 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzolactam compounds and pharmaceutical uses thereof |
| US5166151A (en) * | 1988-03-25 | 1992-11-24 | Merck & Co., Inc. | 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof |
| US5324726A (en) * | 1989-12-18 | 1994-06-28 | Merck & Co., Inc. | Benzodiazepine analogs |
| US5206234A (en) * | 1990-10-22 | 1993-04-27 | Merck & Co., Inc. | Benzolactam analogs as antagonists of cck |
| US5220018A (en) * | 1991-04-10 | 1993-06-15 | Merck & Co., Inc. | Cholecystokinin antagonists |
| CA2068355A1 (en) * | 1991-05-14 | 1992-11-15 | Mark S. Chambers | Benzodiazephine derivatives, compositions containing them and their use in therapy |
| GB9116113D0 (en) * | 1991-07-25 | 1991-09-11 | Merck Sharp & Dohme | Therapeutic agents |
| DE4125457A1 (de) * | 1991-08-01 | 1993-02-04 | Bayer Ag | Verfahren zur herstellung von n-substituierten lactamen |
| ATE188702T1 (de) * | 1991-09-30 | 2000-01-15 | Yoshitomi Pharmaceutical | Thienodiazepinverbindungen und ihre verwendung |
| WO1993007131A1 (en) * | 1991-10-10 | 1993-04-15 | Merck Sharp & Dohme Limited | Benzodiazepine derivatives and their use as antagonists of cholecystokinin and/or gastrin receptors |
| JPH07500589A (ja) * | 1991-10-24 | 1995-01-19 | メルク シヤープ エンド ドーム リミテツド | ベンゾジアゼピン誘導体、並びにコレシストキニン及び／又はガストリンレセプターのアンタゴニストとしての該誘導体の使用 |
| WO1993008175A1 (en) * | 1991-10-24 | 1993-04-29 | Glaxo Group Limited | Benzodiazepine derivatives as antagonists of gastrin and/or cholecystokinin |
| US5428031A (en) * | 1991-12-03 | 1995-06-27 | Merck & Co., Inc. | Methods of treating cardiac arrhythmia |
| EP0549039B1 (en) * | 1991-12-20 | 1995-08-09 | MERCK SHARP & DOHME LTD. | 3-Phenylureido-1,4-Benzodiazepinones and their use as cholecystokinin or gastrin antagonists |
| ZA93436B (en) * | 1992-01-24 | 1993-08-25 | Chugai Pharmaceutical Co Ltd | Benzopyran derivatives |
| GB9203790D0 (en) * | 1992-02-21 | 1992-04-08 | Merck Sharp & Dohme | Therapeutic agents |
| US5597915A (en) * | 1992-03-16 | 1997-01-28 | Merck Sharp & Dohme Ltd. | Benzodiazepine derivatives, compositions containing them and their use in therapy |
| IT1254558B (it) * | 1992-03-26 | 1995-09-25 | Mini Ricerca Scient Tecnolog | Composti a base di 3,4-diaril-(5h)-furan-2-one ad attivita' fungicida 3 |
| GB9209518D0 (en) * | 1992-05-01 | 1992-06-17 | Merck Sharp & Dohme | Therapeutic agents |
| US5360802A (en) * | 1992-05-11 | 1994-11-01 | Merck Sharpe & Dohme Ltd. | Benzodiazepine derivatives, compositions containing them and their use in therapy |
| GB9218412D0 (en) * | 1992-08-28 | 1992-10-14 | Merck Sharp & Dohme | Therapeutic agents |
| US5428157A (en) * | 1993-11-22 | 1995-06-27 | Merck & Co., Inc. | 3-acylaminobenzodiazepines |
| US5438055A (en) * | 1993-11-22 | 1995-08-01 | Merck & Co., Inc. | Antiarrhythmic benzodiazepines |
| US5426185A (en) * | 1993-11-22 | 1995-06-20 | Merck & Co., Inc. | Antiarrhythmic benzodiazepines |
| US5439906A (en) * | 1993-11-22 | 1995-08-08 | Merck & Co., Inc. | Antiarrhythmic benzodiazepines |
| US5441950A (en) * | 1994-06-09 | 1995-08-15 | G. D. Searle & Co. | Substituted dibenzoxazepine and dibenzthiazepine carbamate compounds, pharmaceutical compositions and methods of use |
-
1995
- 1995-08-17 ES ES95930197T patent/ES2139933T3/es not_active Expired - Lifetime
- 1995-08-17 KR KR1019970701009A patent/KR970705395A/ko not_active Application Discontinuation
- 1995-08-17 AU AU33667/95A patent/AU692300B2/en not_active Ceased
- 1995-08-17 CZ CZ97485A patent/CZ285008B6/cs not_active IP Right Cessation
- 1995-08-17 MX MX9701195A patent/MX9701195A/es unknown
- 1995-08-17 AT AT95930197T patent/ATE186463T1/de not_active IP Right Cessation
- 1995-08-17 PL PL95319104A patent/PL319104A1/xx unknown
- 1995-08-17 WO PCT/US1995/010500 patent/WO1996005839A1/en not_active Application Discontinuation
- 1995-08-17 SK SK222-97A patent/SK282019B6/sk unknown
- 1995-08-17 BR BR9508608A patent/BR9508608A/pt not_active Application Discontinuation
- 1995-08-17 DK DK95930197T patent/DK0776208T3/da active
- 1995-08-17 CA CA002195974A patent/CA2195974C/en not_active Expired - Fee Related
- 1995-08-17 DE DE69513295T patent/DE69513295T2/de not_active Expired - Fee Related
- 1995-08-17 RU RU97104124A patent/RU2149161C1/ru active
- 1995-08-17 EP EP95930197A patent/EP0776208B1/en not_active Expired - Lifetime
- 1995-08-17 JP JP8508203A patent/JPH10504570A/ja active Pending
- 1995-08-17 HU HU9701275A patent/HU220635B1/hu not_active IP Right Cessation
- 1995-08-17 CN CN95195291A patent/CN1158568A/zh active Pending
- 1995-08-17 US US08/516,226 patent/US5658901A/en not_active Expired - Fee Related
- 1995-08-17 NZ NZ291988A patent/NZ291988A/en unknown
-
1997
- 1997-02-12 BG BG101227A patent/BG63032B1/bg unknown
- 1997-02-17 NO NO970731A patent/NO970731L/no not_active Application Discontinuation
- 1997-02-17 FI FI970668A patent/FI970668A0/fi unknown
-
2000
- 2000-02-04 GR GR20000400287T patent/GR3032592T3/el not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1694874B (zh) * | 2002-09-20 | 2010-06-09 | 阿罗治疗有限公司 | 苯并二氮杂*衍生物以及包含它们的药用组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX9701195A (es) | 1997-05-31 |
| FI970668A (fi) | 1997-02-17 |
| PL319104A1 (en) | 1997-07-21 |
| KR970705395A (ko) | 1997-10-09 |
| BG63032B1 (bg) | 2001-02-28 |
| ATE186463T1 (de) | 1999-11-15 |
| SK282019B6 (sk) | 2001-10-08 |
| EP0776208A4 (en) | 1997-12-29 |
| AU692300B2 (en) | 1998-06-04 |
| DE69513295D1 (de) | 1999-12-16 |
| CZ285008B6 (cs) | 1999-04-14 |
| AU3366795A (en) | 1996-03-14 |
| JPH10504570A (ja) | 1998-05-06 |
| US5658901A (en) | 1997-08-19 |
| NZ291988A (en) | 1998-11-25 |
| BG101227A (en) | 1998-03-31 |
| NO970731D0 (no) | 1997-02-17 |
| ES2139933T3 (es) | 2000-02-16 |
| HUT76811A (en) | 1997-11-28 |
| CA2195974A1 (en) | 1996-02-29 |
| FI970668A0 (fi) | 1997-02-17 |
| EP0776208A1 (en) | 1997-06-04 |
| NO970731L (no) | 1997-02-17 |
| EP0776208B1 (en) | 1999-11-10 |
| CA2195974C (en) | 2000-12-05 |
| DE69513295T2 (de) | 2000-06-08 |
| BR9508608A (pt) | 1997-12-30 |
| HU220635B1 (hu) | 2002-03-28 |
| WO1996005839A1 (en) | 1996-02-29 |
| SK22297A3 (en) | 1997-09-10 |
| CZ48597A3 (en) | 1997-09-17 |
| GR3032592T3 (en) | 2000-05-31 |
| RU2149161C1 (ru) | 2000-05-20 |
| DK0776208T3 (da) | 2000-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1158568A (zh) | 2，3-二氢-1(2，2，2-三氟乙基)-2-氧代-5-苯基-1h-1，4-苯并二氮杂䓬 | |
| US5633251A (en) | N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepines | |
| US5597818A (en) | Methods of treating cardiac arrhythmia | |
| EP0830350B1 (en) | n-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1h-benzo[b][1,5]diazepin-3-yl)-acetamides | |
| US5631251A (en) | 5-cyclopropyl-1,4 benzodiazepine-2-ones | |
| HRP20050919A2 (en) | Substituted 1,4-diazepines and uses thereof | |
| EP0833819B1 (en) | Novel n-(2-oxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepin-3yl)-3-amides | |
| US5691331A (en) | N-(2,4-Dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3yl) -3- amides | |
| AU722110B2 (en) | Pharmaceutical preparation | |
| AU703665B2 (en) | Novel N-(2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3 yl)-3-amides | |
| EA025579B1 (ru) | Спиропроизводные, представляющие собой 7-метил-2-[4-метил-6-[4-(трифторметил)фенил]пиримидин-2-ил]-1,7-диазаспиро[4,4]нонан-6-он, его применение и композиция, содержащая данное соединение | |
| EP1390347B1 (en) | Pyrrolidine ester derivatives with oxytocin modulating activity | |
| JPH01165571A (ja) | Ｎ−複素環式アルコール誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| AD01 | Patent right deemed abandoned | ||
| C20 | Patent right or utility model deemed to be abandoned or is abandoned |